Oslo, 17 August 2023: Thor Medical ASA will release its first half results on
Thursday 31 August 2023 at 07:00 am (CEST).

A presentation of the results followed by a Q&A session will be held on the same
day at 08:00 am at Carnegie's offices at Aker Brygge, Fjordalleen 16, and
through a live webcast. The presentation and the Q&A session can be followed
through a live webcast from our website www.thormedical.no or Thor
Medical webcast Q2
2023 (https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20230831_5).

For further information, please contact:
Brede Ellingsæter, CFO, brede.ellingseter@thormedical.no (https://connect
-eu.notified.com/Tracker?data=OsuHNo5gZJuKSkeUd6Iq_qGQafBfHnF0_z2qp0
-WfFBtsaNKIQVO47szyCsf6BrutM7x7LAp5WYebh1Y1B
-OdQ0jSpzaXPOhB32gG015eDdequxTTjDdK6O3OzOaKgH_000277396724)
Ludvik Sandnes, Chair of the
Board, lsandnes@nordicnanovector.com (https://connect
-eu.notified.com/Tracker?data=RO9FggVXbDLhi1Ze1lSzNNTs6BirijrTBb5LFo829WG1I3D85M
u
JvEcmJ51zJxkf6GLdfAdPIjVFc6zkhhMTLGUPyhOrCIdueEAWjcs
-3LkIh2JEfoBKTbvLmvv3l26M000277396724)
About Thor Medical
Thor Medical is an emerging supplier of radionuclides, alpha particle emitters,
for medical use in cancer therapy. Thor Medical has developed a proprietary
technology for the manufacturing of alpha particle emitters from natural
resources. Its novel production process requires no irradiation in nuclear
reactors, and provides reliable, environmentally friendly supply of
radionuclides for the radiopharmaceutical industry. The high energy deposition
and the short range of alpha particles make it possible to eradicate cancer
cells while minimizing damage to nearby healthy cells. Thor Medical is
headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the
ticker symbol 'TRMED'.?To learn more, visit?www.thormedical.no.

This information is subject to the disclosure requirements pursuant to Section 5
-12 the Norwegian Securities Trading Act